Clinical Trial Update: Bioequivalence Study for Terbinafine 250 mg [Phase 1]

View source ↗

Summary

GlaxoSmithKline completed a Phase 1 bioequivalence study of Terbinafine 250 mg for mycoses.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycoses

Drugs mentioned

• Terbinafine (terbinafine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Mycoses | Phase 1 | Status: COMPLETED